Superworth

Nexalin Technology price to book ratio NXL

Market value divided by the book value of the company's net assets, since 2022.

Today, Nov 2, 2026
0.7×
4-year median
2.5×
Against its 4-year history
4th
percentile: 0 is its lowest day, 100 its highest
4-year range
0.6× to 29.8×
Peer median
3.0×

Nexalin Technology's price to book ratio is 0.7× as of Nov 2, 2026.

That is below its 4-year median of 2.5×, lower than on 96% of days in the last 4 years.

Over that time it ranged from 0.6× in Oct 2023 to 29.8× in Nov 2024.

The median for 10 medical device stocks of a similar size is 3.0×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.7×0.7×5.1×
20252.5×2.3×9.7×
20247.7×0.7×29.8×
20230.9×0.6×1.4×
20220.9×0.8×2.7×

Against its peers

Companies in Medical - Devices nearest Nexalin Technology's size, closest first, today.

CompanyPrice to book ratio
NXLNexalin Technology0.7×
NUWENuwellisn/m
NDRAENDRA Life Sciences1.1×
IRIXIridex3.5×
QTIQT Imaging14.0×
POCIPrecision Optics2.6×
ECORelectroCoren/m
OMOutset Medical0.8×
HYPRHyperfine2.1×
NRXSNeuraxis, INC12.3×
STXSStereotaxis7.2×
Peer median3.0×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Nexalin Technology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.